-$0.25 Earnings Per Share Expected for Pardes Biosciences, Inc. (NASDAQ:PRDS) This Quarter

Wall Street brokerages forecast that Pardes Biosciences, Inc. (NASDAQ:PRDSGet Rating) will report earnings of ($0.25) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Pardes Biosciences’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.23). The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Pardes Biosciences will report full-year earnings of ($1.30) per share for the current year, with EPS estimates ranging from ($1.45) to ($1.14). For the next year, analysts expect that the business will post earnings of $9.02 per share, with EPS estimates ranging from $7.00 to $11.03. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Pardes Biosciences.

Several equities analysts recently weighed in on PRDS shares. Jefferies Financial Group initiated coverage on shares of Pardes Biosciences in a report on Tuesday, January 18th. They issued a “buy” rating and a $25.00 price target on the stock. SVB Leerink initiated coverage on shares of Pardes Biosciences in a research note on Tuesday, March 15th. They issued an “outperform” rating and a $18.00 price objective on the stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Monashee Investment Management LLC purchased a new position in Pardes Biosciences in the 4th quarter worth approximately $8,185,000. Frazier Management LLC acquired a new position in Pardes Biosciences during the fourth quarter worth $40,229,000. TD Asset Management Inc. acquired a new position in Pardes Biosciences during the fourth quarter worth $1,350,000. Foresite Capital Opportunity Management V LLC acquired a new position in Pardes Biosciences during the fourth quarter worth $85,571,000. Finally, Altai Capital Management L.P. purchased a new stake in Pardes Biosciences in the 4th quarter valued at $1,637,000.

Shares of NASDAQ PRDS traded down $0.23 during mid-day trading on Friday, hitting $8.34. The stock had a trading volume of 88,108 shares, compared to its average volume of 331,608. The stock’s 50 day moving average price is $7.87. Pardes Biosciences has a twelve month low of $5.54 and a twelve month high of $17.76.

Pardes Biosciences Company Profile (Get Rating)

Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.

Featured Articles

Get a free copy of the Zacks research report on Pardes Biosciences (PRDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pardes Biosciences (NASDAQ:PRDS)

Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.